Chinese pharmaceutical products manufacturer Xiangxue Pharmaceutical has raised CNY600m ($90.23m) through a public offering of corporate bonds.

Sumitomo Dainippon Pharma has signed an agreement with French biopharmaceutical company Poxel for the development and commercialisation of Type 2 diabetes investigational therapeutic agent, Imeglimin.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Poxel will receive an upfront payment of CNY4.75bn ($41.7m) and Sumitomo will retain the right for commercialisation of the drug in 11 South East Asian countries, including China, South Korea and Taiwan, under the agreement.

The partnership will enable the Japanese pharmaceutical company to launch an innovative new product in the fast-growing Japanese market.

“Zhongzhi Pharmaceutical Holdings has raised HK$61.2m ($7.84m) through the private placement of 40 million shares of its common stock priced at HK$1.53 ($0.2) a share.”

Zhongzhi Pharmaceutical Holdings has raised HK$61.2m ($7.84m) through the private placement of 40 million shares of its common stock priced at HK$1.53 ($0.2) a share.

The Chinese pharmaceutical company plans to use the funds to expand its distribution network and towards research and development activities.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Chinese pharmaceutical company Shandong Lukang Pharmaceutical plans to form a medical technology joint venture (JV) company based in China with a capital of CNY66.67m ($10.02m).

Shandong Lukang will invest CNY30m ($4.51m) in the JV to secure a 45% stake.